Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP576966.RAuv4RHho4jDt3R1c-HyHOlnOYGnc1vxWw4LuyB-lyW90130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP576966.RAuv4RHho4jDt3R1c-HyHOlnOYGnc1vxWw4LuyB-lyW90130_assertion type Assertion NP576966.RAuv4RHho4jDt3R1c-HyHOlnOYGnc1vxWw4LuyB-lyW90130_head.
- NP576966.RAuv4RHho4jDt3R1c-HyHOlnOYGnc1vxWw4LuyB-lyW90130_assertion description "[Imatinib mesylate (Gleevec, STI-571) is an inhibitor of ABL tyrosine kinase activity that has been remarkably effective in slowing disease progression in patients with chronic phase chronic myelogenous leukemia, but the emergence of imatinib resistance underscores the need for additional therapies.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP576966.RAuv4RHho4jDt3R1c-HyHOlnOYGnc1vxWw4LuyB-lyW90130_provenance.
- NP576966.RAuv4RHho4jDt3R1c-HyHOlnOYGnc1vxWw4LuyB-lyW90130_assertion evidence source_evidence_literature NP576966.RAuv4RHho4jDt3R1c-HyHOlnOYGnc1vxWw4LuyB-lyW90130_provenance.
- NP576966.RAuv4RHho4jDt3R1c-HyHOlnOYGnc1vxWw4LuyB-lyW90130_assertion SIO_000772 15781610 NP576966.RAuv4RHho4jDt3R1c-HyHOlnOYGnc1vxWw4LuyB-lyW90130_provenance.
- NP576966.RAuv4RHho4jDt3R1c-HyHOlnOYGnc1vxWw4LuyB-lyW90130_assertion wasDerivedFrom befree-20150227 NP576966.RAuv4RHho4jDt3R1c-HyHOlnOYGnc1vxWw4LuyB-lyW90130_provenance.
- NP576966.RAuv4RHho4jDt3R1c-HyHOlnOYGnc1vxWw4LuyB-lyW90130_assertion wasGeneratedBy ECO_0000203 NP576966.RAuv4RHho4jDt3R1c-HyHOlnOYGnc1vxWw4LuyB-lyW90130_provenance.